Importer of Controlled Substances Application: Sharp Clinical Services, LLC, 48509-48510 [2022-16991]

Download as PDF 48509 Federal Register / Vol. 87, No. 152 / Tuesday, August 9, 2022 / Notices Controlled substance Alfentanil ......................................................................................................................................................................................... Remifentanil .................................................................................................................................................................................... Sufentanil ........................................................................................................................................................................................ Carfentanil ...................................................................................................................................................................................... Tapentadol ...................................................................................................................................................................................... The company plans to import the listed controlled substances for the manufacturing of analytical reference standards and distribution to their research and forensic customers. No other activities for these drug codes are authorized for this registration. Approval of permit applications will occur only when the registrant’s business activity is consistent with what is authorized under 21 U.S.C. 952(a)(2). Authorization will not extend to the import of Food and Drug Administration-approved or nonapproved finished dosage forms for commercial sale. Kristi O’Malley, Assistant Administrator. [FR Doc. 2022–16994 Filed 8–8–22; 8:45 am] BILLING CODE P the online instructions at that site for submitting comments. Upon submission of your comment, you will receive a Comment Tracking Number. Please be aware that submitted comments are not instantaneously available for public view on https://www.regulations.gov. If you have received a Comment Tracking Number, your comment has been successfully submitted and there is no need to resubmit the same comment. SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.33(a), this is notice that on July 7, 2022, Experic LLC, 2 Clarke Drive, Cranbury, New Jersey 08512–3619, applied to be registered as a bulk manufacturer of the following basic class(es) of controlled substance(s): Controlled substance DEPARTMENT OF JUSTICE Psilocybin ........................ Psilocyn ........................... Drug code Schedule 7437 7438 I I Drug Enforcement Administration [Docket No. DEA–1064] Bulk Manufacturer of Controlled Substances Application: Experic LLC Drug Enforcement Administration, Justice. ACTION: Notice of application. AGENCY: Experic LLC has applied to be registered as a bulk manufacturer of basic class(es) of controlled substance(s). Refer to SUPPLEMENTARY INFORMATION listed below for further drug information. DATES: Registered bulk manufacturers of the affected basic class(es), and applicants therefore, may submit electronic comments on or objections to the issuance of the proposed registration on or before October 11, 2022. Such persons may also file a written request for a hearing on the application on or before October 11, 2022. ADDRESSES: The Drug Enforcement Administration requires that all comments be submitted electronically through the Federal eRulemaking Portal, which provides the ability to type short comments directly into the comment field on the web page or attach a file for lengthier comments. Please go to https://www.regulations.gov and follow jspears on DSK121TN23PROD with NOTICES SUMMARY: VerDate Sep<11>2014 18:04 Aug 08, 2022 Jkt 256001 The company plans to bulk manufacture the listed controlled substances for drug codes 7437 (Psilocybin) and 7438 (Psilocyn), planning on germinating mushrooms to be harvested and freeze dried in form of powder to be filled into capsules for use in clinical studies. Kristi O’Malley, Assistant Administrator. [FR Doc. 2022–17012 Filed 8–8–22; 8:45 am] BILLING CODE P DEPARTMENT OF JUSTICE Drug Enforcement Administration [Docket No. DEA–1042] Importer of Controlled Substances Application: Sharp Clinical Services, LLC Drug Enforcement Administration, Justice. ACTION: Notice of application. AGENCY: Frm 00059 Fmt 4703 Sfmt 4703 9737 9739 9740 9743 9780 II II II II II Registered bulk manufacturers of the affected basic class(es), and applicants therefore, may submit electronic comments on or objections to the issuance of the proposed registration on or before September 8, 2022. Such persons may also file a written request for a hearing on the application on or before September 8, 2022. ADDRESSES: The Drug Enforcement Administration requires that all comments be submitted electronically through the Federal eRulemaking Portal, which provides the ability to type short comments directly into the comment field on the web page or attach a file for lengthier comments. Please go to https://www.regulations.gov and follow the online instructions at that site for submitting comments. Upon submission of your comment, you will receive a Comment Tracking Number. Please be aware that submitted comments are not instantaneously available for public view on https://www.regulations.gov. If you have received a Comment Tracking Number, your comment has been successfully submitted and there is no need to resubmit the same comment. All requests for a hearing must be sent to: (1) Drug Enforcement Administration, Attn: Hearing Clerk/OALJ, 8701 Morrissette Drive, Springfield, Virginia 22152; and (2) Drug Enforcement Administration, Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152. All requests for a hearing should also be sent to: Drug Enforcement Administration, Attn: Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152. SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.34(a), this is notice that on May 23, 2022, Sharp Clinical Services, LLC, 2400 Baglyos Circle, Bethlehem, Pennsylvania 18020– 8024, applied to be registered as an importer of the following basic class(es) of controlled substance(s): SUMMARY: PO 00000 Schedule DATES: Controlled substance Sharp Clinical Services, LLC has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to SUPPLEMENTARY INFORMATION listed below for further drug information. Drug code 5-Methoxy-N-Ndimethyltryptamine. Drug code 7431 Schedule I The company plans to import the listed control substances for clinical E:\FR\FM\09AUN1.SGM 09AUN1 48510 Federal Register / Vol. 87, No. 152 / Tuesday, August 9, 2022 / Notices DEPARTMENT OF JUSTICE Morrissette Drive, Springfield, Virginia 22152; and (2) Drug Enforcement Administration, Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152. All requests for a hearing should also be sent to: Drug Enforcement Administration, Attn: Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152. SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.34(a), this is notice that on June 24, 2022, VHG Labs, DBA LGC Standards, 3 Perimeter Road, Manchester, New Hampshire 03103–3341 applied to be registered as an importer of the following basic class(es) of controlled substance(s): Drug Enforcement Administration Controlled substance trials. No other activity for this drug code is authorized for this registration. Approval of permit applications will occur only when the registrant’s business activity is consistent with what is authorized under 21 U.S.C. 952(a)(2). Authorization will not extend to the import of Food and Drug Administration-approved or nonapproved finished dosage forms for commercial sale. Kristi O’Malley, Assistant Administrator. [FR Doc. 2022–16991 Filed 8–8–22; 8:45 am] BILLING CODE P Drug code Schedule [Docket No. DEA–1053] Importer of Controlled Substances Application: VHG Labs, DBA LGC Standards Drug Enforcement Administration, Justice. ACTION: Notice of application. AGENCY: VHG Labs, DBA LGC Standards has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to SUPPLEMENTARY INFORMATION listed below for further drug information. DATES: Registered bulk manufacturers of the affected basic class(es), and applicants therefore, may submit electronic comments on or objections to the issuance of the proposed registration on or before September 8, 2022. Such persons may also file a written request for a hearing on the application on or before September 8, 2022. ADDRESSES: The Drug Enforcement Administration requires that all comments be submitted electronically through the Federal eRulemaking Portal, which provides the ability to type short comments directly into the comment field on the web page or attach a file for lengthier comments. Please go to https://www.regulations.gov and follow the online instructions at that site for submitting comments. Upon submission of your comment, you will receive a Comment Tracking Number. Please be aware that submitted comments are not instantaneously available for public view on https://www.regulations.gov. If you have received a Comment Tracking Number, your comment has been successfully submitted and there is no need to resubmit the same comment. All requests for a hearing must be sent to: (1) Drug Enforcement Administration, Attn: Hearing Clerk/OALJ, 8701 jspears on DSK121TN23PROD with NOTICES SUMMARY: VerDate Sep<11>2014 18:04 Aug 08, 2022 Jkt 256001 Mephedrone (4-Methyl-Nmethylcathinone). 2,5Dimethoxyamphetamine. Bufotenine ................ Psilocybin ................. Alphamethandol ........ Amphetamine ........... 1248 I 7396 I 7433 7437 9605 1100 I I I II The company plans to import the listed controlled substances for distribution for analytical testing purposes. No other activity for this drug code is authorized for this registration. Approval of permit applications will occur only when the registrant’s business activity is consistent with what is authorized under 21 U.S.C. 952(a)(2). Authorization will not extend to the import of Food and Drug Administration-approved or nonapproved finished dosage forms for commercial sale. Kristi O’Malley, Assistant Administrator. [FR Doc. 2022–16996 Filed 8–8–22; 8:45 am] BILLING CODE P DEPARTMENT OF JUSTICE Drug Enforcement Administration listed below for further drug information. Registered bulk manufacturers of the affected basic class(es), and applicants therefore, may submit electronic comments on or objections to the issuance of the proposed registration on or before September 8, 2022. Such persons may also file a written request for a hearing on the application on or before September 8, 2022. DATES: The Drug Enforcement Administration requires that all comments be submitted electronically through the Federal eRulemaking Portal, which provides the ability to type short comments directly into the comment field on the web page or attach a file for lengthier comments. Please go to https://www.regulations.gov and follow the online instructions at that site for submitting comments. Upon submission of your comment, you will receive a Comment Tracking Number. Please be aware that submitted comments are not instantaneously available for public view on https://www.regulations.gov. If you have received a Comment Tracking Number, your comment has been successfully submitted and there is no need to resubmit the same comment. All requests for a hearing must be sent to: (1) Drug Enforcement Administration, Attn: Hearing Clerk/OALJ, 8701 Morrissette Drive, Springfield, Virginia 22152; and (2) Drug Enforcement Administration, Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152. All requests for a hearing should also be sent to: Drug Enforcement Administration, Attn: Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152. ADDRESSES: In accordance with 21 CFR 1301.34(a), this is notice that on February 3, 2022, Stepan Company, 100 West Hunter Avenue, Maywood, New Jersey 07607– 1021, applied to be registered as an importer of the following basic class(es) of controlled substance(s): SUPPLEMENTARY INFORMATION: Controlled substance [Docket No. DEA–998] Importer of Controlled Substances Application: Stepan Company Drug Enforcement Administration, Justice. ACTION: Notice of application. AGENCY: Stepan Company has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to SUPPLEMENTARY INFORMATION SUMMARY: PO 00000 Frm 00060 Fmt 4703 Sfmt 4703 Coca Leaves ............ Drug code 9040 Schedule I The company plans to import the listed controlled substance in bulk for the manufacture of controlled substances for distribution to its customers. No other activity for this drug code is authorized for this registration. No other activity for this drug code is authorized for this registration. E:\FR\FM\09AUN1.SGM 09AUN1

Agencies

[Federal Register Volume 87, Number 152 (Tuesday, August 9, 2022)]
[Notices]
[Pages 48509-48510]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-16991]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-1042]


Importer of Controlled Substances Application: Sharp Clinical 
Services, LLC

AGENCY: Drug Enforcement Administration, Justice.

ACTION: Notice of application.

-----------------------------------------------------------------------

SUMMARY: Sharp Clinical Services, LLC has applied to be registered as 
an importer of basic class(es) of controlled substance(s). Refer to 
Supplementary Information listed below for further drug information.

DATES: Registered bulk manufacturers of the affected basic class(es), 
and applicants therefore, may submit electronic comments on or 
objections to the issuance of the proposed registration on or before 
September 8, 2022. Such persons may also file a written request for a 
hearing on the application on or before September 8, 2022.

ADDRESSES: The Drug Enforcement Administration requires that all 
comments be submitted electronically through the Federal eRulemaking 
Portal, which provides the ability to type short comments directly into 
the comment field on the web page or attach a file for lengthier 
comments. Please go to https://www.regulations.gov and follow the 
online instructions at that site for submitting comments. Upon 
submission of your comment, you will receive a Comment Tracking Number. 
Please be aware that submitted comments are not instantaneously 
available for public view on https://www.regulations.gov. If you have 
received a Comment Tracking Number, your comment has been successfully 
submitted and there is no need to resubmit the same comment. All 
requests for a hearing must be sent to: (1) Drug Enforcement 
Administration, Attn: Hearing Clerk/OALJ, 8701 Morrissette Drive, 
Springfield, Virginia 22152; and (2) Drug Enforcement Administration, 
Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, 
Springfield, Virginia 22152. All requests for a hearing should also be 
sent to: Drug Enforcement Administration, Attn: Administrator, 8701 
Morrissette Drive, Springfield, Virginia 22152.

SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.34(a), this 
is notice that on May 23, 2022, Sharp Clinical Services, LLC, 2400 
Baglyos Circle, Bethlehem, Pennsylvania 18020-8024, applied to be 
registered as an importer of the following basic class(es) of 
controlled substance(s):

------------------------------------------------------------------------
                                           Drug
          Controlled substance             code          Schedule
------------------------------------------------------------------------
5-Methoxy-N-N-dimethyltryptamine.......     7431  I
------------------------------------------------------------------------

    The company plans to import the listed control substances for 
clinical

[[Page 48510]]

trials. No other activity for this drug code is authorized for this 
registration.
    Approval of permit applications will occur only when the 
registrant's business activity is consistent with what is authorized 
under 21 U.S.C. 952(a)(2). Authorization will not extend to the import 
of Food and Drug Administration-approved or non-approved finished 
dosage forms for commercial sale.

Kristi O'Malley,
Assistant Administrator.
[FR Doc. 2022-16991 Filed 8-8-22; 8:45 am]
BILLING CODE P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.